Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH003 + Toripalimab in Advanced Melanoma and PDAC
NCT05031494Phase 2Completed
- Sponsor
- Eucure Biopharma
- Start
- Dec 2021
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label trial of ciltistotug in melanoma and pancreatic ductal adenocarcinoma (PDAC) (3 arms), sponsored by Eucure Biopharma. Primary endpoint: Objective Response Rate at 1 year. Started Dec 2021; status: completed.
02
Drugs
ciltistotug
03
Conditions
melanomapancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05031494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05031494.